Navigation Links
PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
Date:6/8/2009

INCLINE VILLAGE, Nev., June 8 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the second quarter ended June 30, 2009 of approximately $125 million, as compared with $106 million for the second quarter of 2008. The increase is due primarily to royalty revenues driven by higher product sales of Avastin(R), and Lucentis(R), which are marketed by Genentech, and sales of Tysabri(R), which is marketed by Elan. Royalty revenues are based on first quarter product sales by PDL's licensees and include $18.7 million for Synagis(R), which is marketed by MedImmune. Also included in the second quarter revenue estimate is the second and final installment of $12.5 million from Alexion based on the companies' December 2008 settlement and license agreement. When compared with 2008, royalty revenue for foreign sourced sales was negatively impacted by changes in foreign exchange rates; approximately 50 percent of underlying product sales is in currencies other than U.S. dollars.

The above guidance is preliminary and actual published results may differ from such guidance. PDL plans to release its financial results for the second quarter 2009 on August 6, and will hold a conference call to discuss financial results and provide an update on company activities. Additional information regarding the call will be announced in late July.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payme
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...RNewswire/ - Aegera Therapeutics Inc. announced to...d Phase 2B study of AEG35156, a targeted antisense... oncology indications. ,, The study, entitled "...nked Inhibitor of Apoptosis (XIAP) Antisense AEG35... and Idarubicin in AML Following Failure of a Sing...
(Date:11/19/2009)...nd is honored by latest award for revolutionary he...PRWEB) November 16, 2009 -- Popular Science Magazi...ring aid from InSound Medical a winner of its cove...ategory.    Chosen from thousa...in the hearing canal for up to four months while p...
(Date:11/18/2009)...titute of Standards and Technology (NIST) has demo...or detecting and measuring elusive hazards such as...ge in food or pesticides distributed in soil by wi...e than conventional techniques for detecting trace...lecules, having distinct electrically positive and...
(Date:11/18/2009)...ity Belfast are developing new sensors to detect c...n the fight against the threat of terrorist attack...wipe, an individual or crime scene to gather a sam...t that can detect the presence of chemicals within... to be made in response to terrorist threats. , ...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3Prototype NIST method detects and measures elusive hazards 2New technology detects chemical weapons in seconds 2
...uct line in the United S...agnostics and Response,Biomedical have entered int...e first line of cardiovascular tests for Response ...tform, the RAMP(R) 200 (Rapid Analyte Measurement ...eady used in laboratories worldwide for,West Nile ...
...Newswire-FirstCall/ --,Kiwa Bio-Tech Products Grou... that Kiwa Bio-Tech Products (Shandong) Co., Ltd. ...totaling RMB 150 million (over US$21,million) with...Co., Ltd.,and other distributors. Delivery of prod...m August 2008 through March 2009., Prior to enter...
...axy,Pharmaceuticals Inc. (RPI), a wholly owned sub...gaon, India announced today that under an,agreemen... an authorized,generic of Omeprazole 40 mg Capsule...is indicated for the treatment of acid-related dis... syndrome. The most common,side effects of Prilose...
Other Biology Technology:Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 3Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract 2Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract 3Ranbaxy Launches Omeprazole 40 mg Capsules 2
(Date:11/20/2009)...RBOR, Mich.---We,ve all read studies about the hea...ing is true at the molecular level, where amino ac... damage when single than when paired up with other... of Michigan, along with colleagues in Belgium, ha...ts single cysteines. The research appears in the N...
(Date:11/20/2009)...key question in the origin of biological molecules...billions of years ago from simple precursors. Now,...ers in Italy have reconstructed one of the earlies...f RNA from individual subunits using nothing but w...was one of the first biological molecules present,...
(Date:11/20/2009)... release is available in German . , In the ...nvestigation , Dr. Stefanie Eyerich and Dr. Kilian...ial College London and Istituto Dermopatico dell,I...scovery. It represents a milestone on the way to d...kin diseases such as psoriasis and allergic reacti...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Gen Probe Reports Financial Results for Second Quarter 2009 53283 1Gen Probe Reports Financial Results for Second Quarter 2009 53283 2Gen Probe Reports Financial Results for Second Quarter 2009 53283 3Gen Probe Reports Financial Results for Second Quarter 2009 53283 4Gen Probe Reports Financial Results for Second Quarter 2009 53283 5Gen Probe Reports Financial Results for Second Quarter 2009 53283 6Gen Probe Reports Financial Results for Second Quarter 2009 53283 7Gen Probe Reports Financial Results for Second Quarter 2009 53283 8Gen Probe Reports Financial Results for Second Quarter 2009 53283 9Gen Probe Reports Financial Results for Second Quarter 2009 53283 10Gen Probe Reports Financial Results for Second Quarter 2009 53283 11Gen Probe Reports Financial Results for Second Quarter 2009 53283 12Gen Probe Reports Financial Results for Second Quarter 2009 53283 13Gen Probe Reports Financial Results for Second Quarter 2009 53283 14Gen Probe Reports Financial Results for Second Quarter 2009 53283 15Gen Probe Reports Financial Results for Second Quarter 2009 53283 16Gen Probe Reports Financial Results for Second Quarter 2009 53283 17Gen Probe Reports Financial Results for Second Quarter 2009 53283 18Gen Probe Reports Financial Results for Second Quarter 2009 53283 19Gen Probe Reports Financial Results for Second Quarter 2009 53283 20Gen Probe Reports Financial Results for Second Quarter 2009 53283 21Gen Probe Reports Financial Results for Second Quarter 2009 53283 22Millions of Pennsylvanians Could Lose Private Insurance Study Shows 53279 1Millions of Pennsylvanians Could Lose Private Insurance Study Shows 53279 2Muscle Density Linked to Disability 53275 1Muscle Density Linked to Disability 53275 2
...GAN The 102nd Annual International Meeting of the...ngineers will convene June 29 - July 2, at the Rho...n Providence, RI. , More than 1100 technical pre...soil and water quality, pesticide application tech... renewable energy, food safety, and more. , Speci...
...available in French and Spanish . , Montreal,...are joining forces to protect and conserve the Mon... America,s shared environment. , Although the mon...er of extinction, its unique multigenerational mig...angered biological phenomenon due to threats to th...
... flies has shown that enhancing the production of ...on of plaques and neuron death associated with Alz...fespan. , The buildup of amyloid-beta protein pl...eimer,s, and one that is believed to contribute to...ew up and clear these plaques, and deficiencies in...
Other Biology News:2008 ASABE Annual International Meeting 2Continental plan to protect the monarch's migratory journey 2
Peptide Antibody from Proteintech Group, Inc.
...r system for large format and medium throughput 2-...t gels (26 x 20 cm) simultaneously.Use with 18- or...mm or 1.5-mm pre-assembled hinged gel cassettes.In...uilt-in ceramic heat exchanger and buffer circulat...
ELF® 97 Immunohistochemistry Kit from Molecular Probes (Invitrogen)
Bovine Albumin from Bovine Serum, BODIPY FL conjugated/tagged from Molecular Probes (Invitrogen)
Biology Products: